This post was originally published on this site The Multiple Myeloma Research Foundation (MMRF) is reworking its executive team, with a focus on improving multiple myeloma patient outcomes and advancing its precision medicine program. Steve Labkoff, MD, becomes the organization’s first chief data officer, while Michael Andreini is the new chief operating officer. Meanwhile, Daniel Auclair,…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Partners to Develop and Market TNB-383B Antibody for Multiple Myeloma
This post was originally published on this site The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new collaboration between AbbVie, Teneobio, and its affiliate TeneoOne. Under terms of the agreement, TeneoOne will continue to develop TNB-383B through Phase 1 clinical…
Mesothelioma is Main Cause of Death Among Patients with Asbestos-related Diseases
This post was originally published on this site More than half of all deaths related to asbestos exposure is caused by malignant mesothelioma, a new study has shown. The study, “Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis,” was published in the journal Canadian Respiratory Journal. Asbestos is known to be responsible for several…
Uncommon Case of Sarcoidosis Found in ARDS Patient, Study Reports
This post was originally published on this site A case study diagnosing sarcoidosis upon autopsy in a patient with acute respiratory distress syndrome (ARDS) of unknown cause highlights the importance of physicians taking into account this uncommon disease association for quicker diagnosis and treatment. The study, “Sarcoidosis Presenting as Acute Respiratory Distress Syndrome,” was published in…
FDA Revising ‘Draft Guidance’ on Developing Treatments for Rare Diseases
This post was originally published on this site The U.S. Food and Drug Administration (FDA) is updating its 2015 draft guidelines for drug discovery in rare diseases, with new guidance on natural history — how disorders such as spinal muscle atrophy (SMA) run their course if untreated — the choice of “efficacy endpoints” in clinical…
Sarcoidosis Death Rate Rose in US Between 1999 and 2016, Study Reports
This post was originally published on this site Deaths attributed to sarcoidosis as the primary underlying cause increased between 1999 and 2016 in the United States, according to a recent observational study. The study, “Sarcoidosis deaths in the United States: 1999–2016,” published in the journal Respiratory Medicine, compared death rates among different regions, races, genders,…
Dutch Cardiologists Using Ventripoint’s AI Tool for Early Diagnosis of PH in Sarcoidosis
This post was originally published on this site Two cardiologists in the Netherlands are using an artificial intelligence (AI) tool called the VMS Heart Analysis System, developed by Ventripoint Diagnostics, for the early diagnosis of pulmonary hypertension in sarcoidosis patients. With this tool, Marco Post, MD, PhD, and Marloes Huitema, MD, at the St. Antonius…
Xeljanz Successfully Used to Treat Patient with Disfiguring Sarcoidosis
This post was originally published on this site A research team at Yale School of Medicine successfully treated a person with disfiguring sarcoidosis with Xeljanz (tofacitinib) — an existing approved treatment against rheumatoid arthritis — resulting in a near-complete disappearance of skin lesions. The findings were published in the New England Journal of Medicine in…
$12.5M Grant to Help City of Hope Develop New Lymphoma Immunotherapies
This post was originally published on this site The National Cancer Institute (NCI) has awarded a five-year $12.5 million grant to City of Hope that may help improve treatment by using a vaccine, develop an immunotherapy to shut down a gene involved in B-Cell non-Hodgkin’s lymphoma, and understand who is at risk of developing a…
Exposure to Glyphosate in Herbicides Increases Risk of Non-Hodgkin’s Lymphoma, Study Says
This post was originally published on this site Exposure to glyphosate, a common broad-spectrum herbicide used worldwide, increases the risk of non-Hodgkin’s lymphoma (NHL) by 41 percent in humans, a study says. The study, “Exposure to Glyphosate-Based Herbicides and Risk for Non-Hodgkin Lymphoma: A Meta-Analysis and Supporting Evidence,” were published in Mutation Research/Reviews in Mutation…
FDA OKs Phase 1 Trial to Test TJC4 in Solid Tumors, Lymphoma
This post was originally published on this site I-Mab Biopharma is planning the first-in-human U.S. clinical study evaluating the safety, tolerability, and efficacy of its investigational candidate TJC4 as a treatment for solid tumors and lymphoma. The Phase 1/1b trial will explore TJC4 alone and in combination with other therapies, and is expected to launch…
First Patient Dosed in Trial of ADCT-402 for Advanced Non-Hodgkin’s Lymphoma
This post was originally published on this site A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imfinzi (durvalumab) in multiple types of advanced non-Hodgkin’s lymphoma has dosed the first patient. The study (NCT03685344) is for adults with advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or follicular lymphoma (FL) who have relapsed or…